Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Jacobs Levy Equity Management Inc. raised its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 50.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,803 shares of the company's stock after buying an additional 67,559 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.54% of Entrada Therapeutics worth $3,225,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of TRDA. Vanguard Group Inc. lifted its holdings in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company's stock worth $15,288,000 after purchasing an additional 13,742 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Entrada Therapeutics by 13.4% in the second quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company's stock worth $1,787,000 after purchasing an additional 14,838 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Entrada Therapeutics by 87.2% during the second quarter. Allspring Global Investments Holdings LLC now owns 27,631 shares of the company's stock valued at $394,000 after buying an additional 12,868 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company's stock valued at $526,000 after buying an additional 7,452 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of Entrada Therapeutics by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company's stock worth $190,000 after acquiring an additional 7,682 shares in the last quarter. Institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Stock Up 6.3 %

NASDAQ TRDA traded up $1.27 during trading on Friday, hitting $21.59. The company's stock had a trading volume of 81,524 shares, compared to its average volume of 135,822. Entrada Therapeutics, Inc. has a 52 week low of $11.35 and a 52 week high of $21.63. The firm has a 50 day moving average price of $18.09 and a 200 day moving average price of $16.47. The firm has a market cap of $807.90 million, a P/E ratio of 13.58 and a beta of -0.18.

Insiders Place Their Bets

In other news, COO Nathan J. Dowden sold 1,904 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.07, for a total value of $28,693.28. Following the sale, the chief operating officer now directly owns 125,996 shares in the company, valued at approximately $1,898,759.72. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Natarajan Sethuraman sold 2,642 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the sale, the insider now directly owns 183,816 shares of the company's stock, valued at approximately $2,773,783.44. The trade was a 1.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,934 shares of company stock worth $515,582 in the last ninety days. Insiders own 7.59% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on TRDA shares. Roth Mkm started coverage on Entrada Therapeutics in a report on Thursday. They set a "buy" rating and a $29.00 price objective on the stock. Oppenheimer raised their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 6th. Roth Capital raised shares of Entrada Therapeutics to a "strong-buy" rating in a research note on Thursday. Finally, HC Wainwright upped their target price on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, November 6th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.